Ghrelin as a neuroprotective and palliative agent in alzheimer's and parkinson's disease

Current Pharmaceutical Design

Volumn 19, Issue 38, 2013, Pages 6773-6790

  dos Santos, Vanessa V ^a   Rodrigues, Ana Lúcia S ^a   De Lima, Thereza C ^a   De Barioglio, Susana R ^b   Raisman Vozari, Rita ^c   Prediger, Rui D ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Alzheimer s disease; Anxiety; Depression; Ghrelin; Learning and memory; Neuroprotection; Parkinson s disease

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GHRELIN; GROWTH HORMONE; GROWTH HORMONE SECRETAGOGUE; SIGNAL PEPTIDE; NEUROPROTECTIVE AGENT;

ADIPOGENESIS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEPRESSION; ENERGY BALANCE; EPILEPSY; FOOD INTAKE; HUMAN; HYPOTHALAMUS; MEMORY; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SPINAL CORD INJURY; TRAUMATIC BRAIN INJURY; ANIMAL; ANXIETY DISORDER; DRUG EFFECT; LEARNING; PALLIATIVE THERAPY; PHYSIOLOGY; REVIEW;

ALZHEIMER DISEASE; ANIMALS; ANXIETY DISORDERS; GHRELIN; HUMANS; LEARNING; MEMORY; NEUROPROTECTIVE AGENTS; PALLIATIVE CARE; PARKINSON DISEASE;

EID: 84890280554     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990411     Document Type: Article

References (170)

1. [1] Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006; 368: 387-403.
2. [2] Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-7.
3. [3] Larson EB, Shadlen MF, Wang L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 2004; 140: 501-9.
4. [4] Artero S, Tierney MC, Touchon J, Ritchie K. Prediction of transition from cognitive impairment to senile dementia: a prospective, longitudinal study. Acta Psychiatr Scand 2003; 107: 390-3.
5. [5] Lambon Ralph MA, Patterson K, Graham N, Dawson K, Hodges JR. Homogeneity and heterogeneity in mild cognitive impairment and Alzheimer's disease: a cross-sectional and longitudinal study of 55 cases. Brain 2003; 126: 2350-62.
6. [6] Cotman CW, Su JH. Mechanisms of neuronal death in Alzheimer's disease. Brain Pathol 1996; 6: 493-506.
7. [7] Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci 2003; 26: 81-104.
8. [8] Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neu- rons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988; 28; 345-8.
9. [9] Chaudhuri KR, Healy DG, Schapira AH, Excellence NIfC. Non- motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-45.
10. [10] Momany FA. Conformational analysis of methionine-enkephalin and some analogs. Biochem Biophys Res Commun 1977; 75: 1098-103.
11. [11] Momany FA, Bowers CY, Reynolds GA, Chang D, Hong A, Newlander K. Design, synthesis, and biological activity of peptides which release growth hormone in vitro. Endocrinology 1981; 108: 31-9.
12. [12] Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984; 114: 1537-45.
13. [13] Smith RG, Van der Ploeg LH, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev 1997; 18: 621-45.
14. [14] Korbonits M, Ciccarelli E, Ghigo E, Grossman AB. The growth hormone secretagogue receptor. Growth Horm IGF Res 1999; 9 Suppl A: 93-9.
15. [15] Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
16. [16] Smith RG, Griffin PR, Xu Y, et al. Adenosine: A partial agonist of the growth hormone secretagogue receptor. Biochem Biophys Res Commun 2000; 276: 1306-13.
17. [17] Stengel A, Taché Y. Yin and Yang - the Gastric X/A-like Cell as Possible Dual Regulator of Food Intake. J Neurogastroenterol Motil 2012; 18: 138-49.
18. [18] Furness JB, Hunne B, Matsuda N, et al. Investigation of the presence of ghrelin in the central nervous system of the rat and mouse. Neuroscience 2011; 193: 1-9.
19. [19] Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310: 996-9.
20. [20] Seim I, Collet C, Herington AC, Chopin LK. Revised genomic structure of the human ghrelin gene and identification of novel exons, alternative splice variants and natural antisense transcripts. BMC Genomics 2007; 8: 298.
21. [21] Seim I, Josh P, Cunningham P, Herington A, Chopin L. Ghrelin axis genes, peptides and receptors: recent findings and future challenges. Mol Cell Endocrinol 2011; 340: 3-9.
22. [22] Pemberton C, Wimalasena P, Yandle T, Soule S, Richards M. C-terminal pro-ghrelin peptides are present in the human circulation. Biochem Biophys Res Commun 2003; 310: 567-73.
23. [23] Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 2008; 132: 387-96.
24. [24] Kang K, Zmuda E, Sleeman MW. Physiological role of ghrelin as revealed by the ghrelin and GOAT knockout mice. Peptides 2011; 32: 2236-41.
25. [25] Kojima M, Kangawa K. Ghrelin: from gene to physiological function. Results Probl Cell Differ 2010; 50: 185-205.
26. [26] Soares JB, Leite-Moreira AF. Ghrelin, des-acyl ghrelin and obestatin: three pieces of the same puzzle. Peptides 2008; 29: 1255-70.
27. [27] Nishi Y, Yoh J, Hiejima H, Kojima M. Structures and molecular forms of the ghrelin-family peptides. Peptides 2011; 32: 2175-82.
28. [28] Baldanzi G, Filigheddu N, Cutrupi S, et al. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 2002; 159: 1029-37.
29. [29] Yin X, Li Y, Xu G, An W, Zhang W. Ghrelin fluctuation, what determines its production? Acta Biochim Biophys Sin (Shanghai) 2009; 41: 188-97.
30. [30] Ueno M, Carvalheira JB, Oliveira RL, Velloso LA, Saad MJ. Circulating ghrelin concentrations are lowered by intracerebro- ventricular insulin. Diabetologia 2006; 49: 2449-52.
31. [31] Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Oikawa S. Effects of insulin, leptin, and glucagon on ghrelin secretion from isolated perfused rat stomach. Regul Pept, 2004; 119: 77-81.
32. [32] Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev 2005; 85: 495-522.
33. [33] Floquet N, M'Kadmi C, Perahia D, et al. Activation of the ghrelin receptor is described by a privileged collective motion: a model for constitutive and agonist-induced activation of a sub-class A G- protein coupled receptor (GPCR). J Mol Biol 2010; 395: 769-84.
34. [34] Guan XM, Yu H, Palyha OC, et al. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 1997; 48: 23-9.
35. [35] Kola B, Farkas I, Christ-Crain M, et al. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One 2008; 3: e1797.
36. [36] Jiang H, Betancourt L, Smith RG. Ghrelin amplifies dopamine signaling by cross talk involving formation of growth hormone secretagogue receptor/dopamine receptor subtype 1 heterodimers. Mol Endocrinol 2006; 20: 1772-85.
37. [37] Andrews ZB. The extra-hypothalamic actions of ghrelin on neuronal function. Trends Neurosci 2011; 34: 31-40.
38. [38] Deboer MD. The use of ghrelin and ghrelin receptor agonists as a treatment for animal models of disease: Efficacy and mechanism. Curr Pharm Des 2012 (in press).
39. [39] Strasser F. Clinical Application of Ghrelin. Curr Pharm Des 2012 (in press).
40. [40] Frago LM, Pañeda C, Dickson SL, Hewson AK, Argente J, Chowen JA. Growth hormone (GH) and GH-releasing peptide-6 increase brain insulin-like growth factor-I expression and activate intracellular signaling pathways involved in neuroprotection. Endocrinology 2002; 143: 4113-22.
41. [41] Pañeda C, Arroba AI, Frago LM, et al. Growth hormone-releasing peptide-6 inhibits cerebellar cell death in aged rats. Neuroreport 2003; 14: 1633-5.
42. [42] Chung H, Seo S, Moon M, Park S. Phosphatidylinositol-3- kinase/Akt/glycogen synthase kinase-3 beta and ERK1/2 pathways mediate protective effects of acylated and unacylated ghrelin against oxygen-glucose deprivation-induced apoptosis in primary rat cortical neuronal cells. J Endocrinol 2008; 198: 511-21.
43. [43] Hwang S, Moon M, Kim S, Hwang L, Ahn KJ, Park S. Neuroprotective effect of ghrelin is associated with decreased expression of prostate apoptosis response-4. Endocr J 2009; 56: 609-17.
44. [44] Bansal V, Ryu SY, Blow C, et al. The hormone ghrelin prevents traumatic brain injury induced intestinal dysfunction. J Neurotrauma 2010; 27: 2255-60.
45. [45] Lopez NE, Krzyzaniak MJ, Blow C, et al. Ghrelin prevents disruption of the blood-brain barrier after traumatic brain injury. J Neurotrauma 2012; 29: 385-93.
46. [46] Qi L, Cui X, Dong W, et al. Ghrelin attenuates brain injury after traumatic brain injury and uncontrolled hemorrhagic shock in rats. Mol Med 2012; 18: 186-93.
47. [47] Ersahın M, Toklu HZ, Erzık C, et al. Ghrelin alleviates spinal cord injury in rats via its anti-inflammatory effects. Turk Neurosurg 2011; 21: 599-605.
48. [48] Zhang Q, Huang C, Meng B, Tang T, Shi Q, Yang H. Acute effect of ghrelin on ischemia/reperfusion injury in the rat spinal cord. Int J Mol Sci 2012; 13: 9864-76.
49. [49] Lim E, Lee S, Li E, Kim Y, Park S. Ghrelin protects spinal cord motoneurons against chronic glutamate-induced excitotoxicity via ERK1/2 and phosphatidylinositol-3-kinase/Akt/glycogen synthase kinase-3|3 pathways. Exp Neurol 2011; 230: 114-22.
50. [50] Lee S, Kim Y, Li E, Park S. Ghrelin protects spinal cord motoneurons against chronic glutamate excitotoxicity by inhibiting microglial activation. Korean J Physiol Pharmacol 2012; 16: 43-8.
51. [51] Obay BD, Tasdemir E, Tümer C, Bilgin HM, Atmaca M. Dose dependent effects of ghrelin on pentylenetetrazole-induced oxidative stress in a rat seizure model. Peptides 2008; 29: 448-55.
52. [52] Obay BD, Tasdemir E, Tümer C, Bilgin HM, Sermet A. Antiepileptic effects of ghrelin on pentylenetetrazole-induced seizures in rats. Peptides 2007; 28: 1214-9.
53. [53] Aslan A, Yildirim M, Ayyildiz M, Güven A, Agar E. The role of nitric oxide in the inhibitory effect of ghrelin against penicillin-induced epileptiform activity in rat. Neuropeptides 2009; 43: 295-302.
54. [54] Xu J, Wang S, Lin Y, Cao L, Wang R, Chi Z. Ghrelin protects against cell death of hippocampal neurons in pilocarpine-induced seizures in rats. Neurosci Lett 2009; 453: 58-61.
55. [55] Lee J, Lim E, Kim Y, Li E, Park S. Ghrelin attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. J Endocrinol 2010; 205: 263-70.
56. [56] Diano S, Farr SA, Benoit SC, et al. Ghrelin controls hippocampal spine synapse density and memory performance. Nat Neurosci 2006; 9: 381-8.
57. [57] Moon M, Choi JG, Nam DW, et al. Ghrelin ameliorates cognitive dysfunction and neurodegeneration in intrahippocampal amyloid- (31-42 oligomer-injected mice. J Alzheimers Dis 2011; 23: 147-59).
58. Jiang H, Li LJ, Wang J, Xie JX. Ghrelin antagonizes MPTP- induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra. Exp Neurol 2008; 212: 532-7.
59. [59] Andrews ZB, Erion D, Beiler R, et al. Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. J Neurosci 2009; 29: 14057-65.
60. [60] Moon M, Kim HG, Hwang L, et al. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation. Neurotox Res 2009; 15: 332-47.
61. [61] Dong J, Song N, Xie J, Jiang H. Ghrelin antagonized 1-methyl-4- phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells. J Mol Neurosci 2009; 37: 182-9.
62. [62] Frago LM, Baquedano E, Argente J, Chowen JA. Neuroprotective actions of ghrelin and growth hormone secretagogues. Front Mol Neurosci 2011; 4: 23.
63. [63] Chung H, Kim E, Lee DH, et al. Ghrelin inhibits apoptosis in hypothalamic neuronal cells during oxygen-glucose deprivation. Endocrinology 2007; 148: 148-59.
64. [64] Miao Y, Xia Q, Hou Z, Zheng Y, Pan H, Zhu S. Ghrelin protects cortical neuron against focal ischemia/reperfusion in rats. Biochem Biophys Res Commun 2007; 359: 795-800.
65. [65] Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron 1991; 6: 487-98.
66. [66] Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta- peptide. Nat Rev Mol Cell Biol 2007; 8: 101-12.
67. [67] Rigamonti AE, Pincelli AI, Corrà B, et al. Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. J Endocrinol 2002; 175: R1-5.
68. [68] Proto C, Romualdi D, Cento RM, et al. Plasma levels of neuropeptides in Alzheimer's disease. Gynecol Endocrinol 2006; 22: 213-8.
69. [69] Gahete MD, Rubio A, Córdoba-Chacón J, et al. Expression of the ghrelin and neurotensin systems is altered in the temporal lobe of Alzheimer's disease patients. J Alzheimers Dis 2010; 22: 819-28.
70. [70] Shibata N, Ohnuma T, Kuerban B, Komatsu M, Arai H. Genetic association between ghrelin polymorphisms and Alzheimer's disease in a Japanese population. Dement Geriatr Cogn Disord 2011; 32: 178-81.
71. [71] Theodoropoulou A, Metallinos IC, Psyrogiannis A, Vagenakis GA, Kyriazopoulou V. Ghrelin and leptin secretion in patients with moderate Alzheimer's disease. J Nutr Health Aging 2012; 16: 472-7.
72. [72] Allain H, Bentué-Ferrer D, Akwa Y. Disease-modifying drugs and Parkinson's disease. Prog Neurobiol 2008; 84: 25-39.
73. [73] Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001; 16: 448-58.
74. [74] Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-34.
75. [75] Jenner P. Functional models of Parkinson's disease: a valuable tool in the development of novel therapies. Ann Neurol 2008; 64 Suppl 2: S16-29.
76. [76] Langston JW, Ballard PA. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N Engl J Med 1983; 309: 310.
77. [77] Schmidt N, Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J Neural Transm 2001; 108: 1263-82.
78. [78] Prediger RD, Aguiar AS Jr, Moreira EL, et al. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease. Curr Pharm Des 2011;17: 489-507.
79. [79] Corcuff JB, Krim E, Tison F, et al. Subthalamic nucleus stimulation in patients with Parkinson's disease does not increase serum ghrelin levels. Br J Nutr 2006; 95: 1028-9.
80. [80] Fiszer U, Michalowska M, Baranowska B, et al. Leptin and ghrelin concentrations and weight loss in Parkinson's disease. Acta Neurol Scand 2010; 121: 230-6.
81. [81] Unger MM, Möller JC, Mankel K, et al. Postprandial ghrelin response is reduced in patients with Parkinson's disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson's disease? J Neurol 2011; 258: 982-90.
82. [82] Markaki E, Ellul J, Kefalopoulou Z, et al. The role of ghrelin, neuropeptide Y and leptin peptides in weight gain after deep brain stimulation for Parkinson's disease. Stereotact Funct Neurosurg 2012; 90: 104-12.
83. [83] Andrews ZB, Horvath B, Barnstable CJ, et al. Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease. J Neurosci 2005; 25: 184-91.
84. [84] Jerlhag E, Egecioglu E, Dickson SL, Douhan A, Svensson L, Engel JA. Ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens. Addict Biol 2007; 12: 6-16.
85. [85] Lorefält B, Ganowiak W, Pålhagen S, Toss G, Unosson M, Granérus AK. Factors of importance for weight loss in elderly patients with Parkinson's disease. Acta Neurol Scand 2004; 110: 180-7.
86. [86] Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998; 339: 1105-11.
87. [87] Volkmann J, Allert N, Voges J, Weiss PH, Freund HJ, Sturm V. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology 2001; 56: 548-51.
88. [88] Perlemoine C, Macia F, Tison F, et al. Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in Parkinson's disease. Br J Nutr 2005; 93: 191-8.
89. [89] Cowley MA, Smith RG, Diano S, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003; 37: 649-61.
90. [90] Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006; 21: 916-23.
91. [91] Schenck CH, Mahowald MW. Subclinical REM sleep behavior disorder and its clinical and research implications. Sleep 2008; 31: 1627.
92. [92] Unger MM, Belke M, Menzler K, et al. Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. Sleep 2010; 33: 767-73.
93. [93] Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996; 46: 388-93.
94. [94] Schenck CH, Callies AL, Mahowald MW. Increased percentage of slow-wave sleep in REM sleep behavior disorder (RBD): a reanalysis of previously published data from a controlled study of RBD reported in SLEEP. Sleep 2003; 26: 1066; author reply 1067.
95. [95] Carlini VP, Monzón ME, Varas MM, et al. Ghrelin increases anxiety-like behavior and memory retention in rats. Biochem Biophys Res Commun 2002; 299: 739-43.
96. [96] Carlini VP, Varas MM, Cragnolini AB, et al. Differential role of the hippocampus, amygdala, and dorsal raphe nucleus in regulating feeding, memory, and anxiety-like behavioral responses to ghrelin. Biochem Biophys Res Commun 2004; 313: 635-41.
97. [97] Carlini VP, Martini AC, Schiöth HB, Ruiz RD, Fiol de Cuneo M, de Barioglio SR. Decreased memory for novel object recognition in chronically food-restricted mice is reversed by acute ghrelin administration. Neuroscience 2008; 153: 929-34.
98. [98] Gahete MD, Córdoba-Chacón J, Kineman RD, Luque RM, Castaño JP. Role of ghrelin system in neuroprotection and cognitive functions: implications in Alzheimer's disease. Peptides 2011; 32: 2225-8.
99. [99] Carlini VP, Gaydou RC, Schiöth HB, de Barioglio SR. Selective serotonin reuptake inhibitor (fluoxetine) decreases the effects of ghrelin on memory retention and food intake. Regul Pept 2007; 140: 65-73.
100. [100] Atcha Z, Chen WS, Ong AB, et al. Cognitive enhancing effects of ghrelin receptor agonists. Psychopharmacology (Berl), 2009; 206: 415-27.
101. [101] Carlini VP, Ghersi M, Schiöth HB, de Barioglio SR. Ghrelin and memory: differential effects on acquisition and retrieval. Peptides 2010; 31: 1190-3.
102. [102] Carlini VP, Perez MF, Salde E, Schiöth HB, Ramirez OA, de Barioglio SR. Ghrelin induced memory facilitation implicates nitric oxide synthase activation and decrease in the threshold to promote LTP in hippocampal dentate gyrus. Physiol Behav 2010; 101: 117-23.
103. [103] Chen L, Xing T, Wang M, et al. Local infusion of ghrelin enhanced hippocampal synaptic plasticity and spatial memory through activation of phosphoinositide 3-kinase in the dentate gyrus of adult rats. Eur J Neurosci 2011; 33: 266-75.
104. [104] Albarran-Zeckler RG, Brantley AF, Smith RG. Growth hormone secretagogue receptor (GHS-R1a) knockout mice exhibit improved spatial memory and deficits in contextual memory. Behav Brain Res 2012; 232: 13-9.
105. [105] Rossato JI, Bevilaqua LR, Izquierdo I, Medina JH, Cammarota M. Dopamine controls persistence of long-term memory storage. Science 2009; 325: 1017-20.
106. [106] Ortiz O, Delgado-García JM, Espadas I, et al. Associative learning and CA3-CA1 synaptic plasticity are impaired in D1R null, Drd1a-/- mice and in hippocampal siRNA silenced Drd1a mice. J Neurosci 2010; 30: 12288-300.
107. [107] Kern A, Albarran-Zeckler R, Walsh HE, Smith RG. Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism. Neuron 2012; 73: 317-32.
108. [108] Ghersi MS, Casas SM, Escudero C, et al. Ghrelin inhibited serotonin release from hippocampal slices. Peptides 2011; 32: 2367-71.
109. [109] Wang G, Wang W, Zhao J, Ni Y, Zhou X, Zhang W. Ghrelin prevents neuronal apoptosis and cognitive impairments in sepsis-associated encephalopathy. Neuroreport 2011; 22: 959-64.
110. [110] Ma LY, Zhang DM, Tang Y, et al. Ghrelin-attenuated cognitive dysfunction in streptozotocin-induced diabetic rats. Alzheimer Dis Assoc Disord 2011; 25: 352-63.
111. [111] Wong ML, Licinio J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 2004; 3: 136-51.
112. [112] Kessler RC. The costs of depression. Psychiatr Clin North Am 2012; 35: 1-14.
113. [113] Murray CJ, Lopez AD. Evidence-based health policy--lessons from the Global Burden of Disease Study. Science 1996; 274: 740-3.
114. [114] Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuro Endocrinol Lett 2011; 32: 7-24.
115. [115] Dooneief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 1992; 49: 305-7.
116. [116] Lieberman A. Managing the neuropsychiatric symptoms of Parkinson's disease. Neurology 1998; 50: S33-8 discussion S44-8.
117. [117] Chen P, Kales HC, Weintraub D, et al. Depression in veterans with Parkinson's disease: frequency, co-morbidity, and healthcare utilization. Int J Geriatr Psychiatry 2007; 22: 543-8.
118. [118] Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006; 63: 530-8.
119. [119] Arbus C, Gardette V, Cantet CE, et al. Incidence and predictive factors of depressive symptoms in Alzheimer's disease: the REAL.FR study. J Nutr Health Aging 2011; 15: 609-17.
120. [120] Rapp MA, Schnaider-Beeri M, Purohit DP, Perl DP, Haroutunian V, Sano M. Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression. Am J Geriatr Psychiatry 2008; 16: 168-74.
121. [121] Kanehisa M, Akiyoshi J, Kitaichi T, et al. Administration of antisense DNA for ghrelin causes an antidepressant and anxiolytic response in rats. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1403-7.
122. [122] Lutter M, Sakata I, Osborne-Lawrence S, et al. The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat Neurosci 2008; 11: 752-3.
123. [123] Chuang JC, Perello M, Sakata I, et al. Ghrelin mediates stress-induced food-reward behavior in mice. J Clin Invest 2011; 121: 2684-92.
124. [124] Carlini VP, Machado DG, Buteler F, et al. Acute ghrelin administration reverses depressive-like behavior induced by bilateral olfactory bulbectomy in mice. Peptides 2012; 35: 160-5.
125. [125] Song C, Leonard BE. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 2005; 29: 627-47.
126. [126] Nowak G, Szewczyk B, Wieronska JM, et al. Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull 2003; 61: 159-64.
127. [127] Takahashi K, Murasawa H, Yamaguchi K, et al. Riluzole rapidly attenuates hyperemotional responses in olfactory bulbectomized rats, an animal model of depression. Behav Brain Res 2011; 216: 46-52.
128. [128] Schmid DA, Wichniak A, Uhr M, et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology 2006; 31: 832-44.
129. [129] Barim AO, Aydin S, Colak R, Dag E, Deniz O, Sahin I. Ghrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment. Clin Biochem 2009; 42: 1076-81.
130. [130] Kurt E, Guler O, Serteser M, et al. The effects of electroconvulsive therapy on ghrelin, leptin and cholesterol levels in patients with mood disorders. Neurosci Lett 2007; 426: 49-53.
131. [131] Brunetti L, Recinella L, Orlando G, Michelotto B, Di Nisio C, Vacca M. Effects of ghrelin and amylin on dopamine, norepinephrine and serotonin release in the hypothalamus. Eur J Pharmacol 2002; 454: 189-92.
132. [132] Kluge M, Schüssler P, Dresler M, et al. Effects of ghrelin on psychopathology, sleep and secretion of cortisol and growth hormone in patients with major depression. J Psychiatr Res 2011; 45: 421-6.
133. [133] Nakashima K, Akiyoshi J, Hatano K, et al. Ghrelin gene polymorphism is associated with depression, but not panic disorder. Psychiatr Genet 2008; 18: 257.
134. [134] Kluge M, Schussler P, Schmid D, Uhr M, Kleyer S, Yassouridis A, Steiger A. Ghrelin plasma levels are not altered in major depression. Neuropsychobiology 2009; 59: 199-204.
135. [135] Schanze A, Reulbach U, Scheuchenzuber M, Groschl M, Kornhuber J, Kraus T. Ghrelin and eating disturbances in psychiatric disorders. Neuropsychobiology 2008; 57: 126-30.
136. [136] Rouach V, Bloch M, Rosenberg N, et al. The acute ghrelin response to a psychological stress challenge does not predict the post-stress urge to eat. Psychoneuroendocrinology 2007; 32: 693-702.
137. [137] Kristenssson E, Sundqvist M, Astin M, et al. Acute psychological stress raises plasma ghrelin in the rat. Regul Pept 2006; 134: 114-7.
138. [138] Chuang JC, Zigman JM. Ghrelin's Roles in Stress, Mood, and Anxiety Regulation. Int J Pept 2010; 2010. pii: 460549
139. [139] Schellekens H, Finger BC, Dinan TG, Cryan JF. Ghrelin signalling and obesity: at the interface of stress, mood and food reward. Pharmacol Ther 2012; 135: 316-26.
140. [140] Dantzer R, O'Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011; 36: 426-36.
141. [141] Kaster MP, Gadotti VM, Calixto JB, Santos AR, Rodrigues AL. Depressive-like behavior induced by tumor necrosis factor-a in mice. Neuropharmacology 2012; 62: 419-26.
142. [142] Himmerich H, Sheldrick AJ. TNF-alpha and ghrelin: opposite effects on immune system, metabolism and mental health. Protein Pept Lett 2010; 17: 186-96.
143. [143] Neufeld KM, Kang N, Bienenstock J, Foster JA. Reduced anxietylike behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil 2011; 23: 255-64, e1 19.
144. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13: 701-12.
145. [145] Mayer EA. Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci 2011; 12: 453-66.
146. [146] Skibicka KP, Dickson SL. Ghrelin and food reward: the story of potential underlying substrates. Peptides 2011; 32: 2265-73.
147. [147] Roberts CJ. The effects of stress on food choice, mood and bodyweight in healthy women. In: eds. Nutrition Bulletin 2008; pp. 33-39.
148. [148] Adam TC, Epel ES. Stress, eating and the reward system. Physiol Behav 2007; 91: 449-58.
149. [149] Raspopow K, Abizaid A, Matheson K, Anisman H. Psychosocial stressor effects on cortisol and ghrelin in emotional and non-emotional eaters: influence of anger and shame. Horm Behav 2010; 58: 677-84.
150. [150] Stengel A, Wang L, Taché Y. Stress-related alterations of acyl and desacyl ghrelin circulating levels: mechanisms and functional implications. Peptides 2011; 32: 2208-17.
151. [151] Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-13.
152. [152] Asakawa A, Inui A, Kaga T, et al. A role of ghrelin in neuroendocrine and behavioral responses to stress in mice. Neuroendocrinology 2001; 74: 143-7.
153. [153] Brzozowski T, Konturek PC, Konturek SJ, et al. Exogenous and endogenous ghrelin in gastroprotection against stress-induced gastric damage. Regul Pept 2004; 120: 39-51.
154. [154] Zheng J, Dobner A, Babygirija R, Ludwig K, Takahashi T. Effects of repeated restraint stress on gastric motility in rats. Am J Physiol Regul Integr Comp Physiol 2009; 296: R1358-65.
155. [155] Ochi M, Tominaga K, Tanaka F, et al. Effect of chronic stress on gastric emptying and plasma ghrelin levels in rats. Life Sci 2008; 82: 862-8.
156. [156] Hansson C, Haage D, Taube M, Egecioglu E, Salomé N, Dickson SL. Central administration of ghrelin alters emotional responses in rats: behavioural, electrophysiological and molecular evidence. Neuroscience 2011; 180: 201-11.
157. [157] Spencer SJ, Xu L, Clarke MA, et al. Ghrelin regulates the hypothalamic-pituitary-adrenal axis and restricts anxiety after acute stress. Biol Psychiatry 2012; 72: 457-65.
158. [158] Currie PJ, Khelemsky R, Rigsbee EM, et al. Ghrelin is an orexigenic peptide and elicits anxiety-like behaviors following administration into discrete regions of the hypothalamus. Behav Brain Res 2012; 226: 96-105.
159. [159] Carvajal P, Carlini VP, Schiöth HB, de Barioglio SR, Salvatierra NA. Central ghrelin increases anxiety in the Open Field test and impairs retention memory in a passive avoidance task in neonatal chicks. Neurobiol Learn Mem 2009; 91: 402-7.
160. [160] Zigman JM, Jones JE, Lee CE, Saper CB, Elmquist JK. Expression of ghrelin receptor mRNA in the rat and the mouse brain. J Comp Neurol 2006; 494: 528-48.
161. [161] Broglio F, Benso A, Castiglioni C, et al. The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects. J Clin Endocrinol Metab 2003; 88: 1537-42.
162. [162] Stevanovic D, Milosevic V, Starcevic VP, Severs WB. The effect of centrally administered ghrelin on pituitary ACTH cells and circulating ACTH and corticosterone in rats. Life Sci 2007; 80: 867-72.
163. [163] Jászberényi M, Bujdosó E, Bagosi Z, Telegdy G. Mediation of the behavioral, endocrine and thermoregulatory actions of ghrelin. Horm Behav 2006; 50: 266-73.
164. [164] Ogaya M, Kim J, Sasaki K. Ghrelin postsynaptically depolarizes dorsal raphe neurons in rats in vitro. Peptides 2011; 32: 1606-16.
165. [165] Kristensson E, Sundqvist M, Håkanson R, Lindström E. High gastrin cell activity and low ghrelin cell activity in high-anxiety Wistar Kyoto rats. J Endocrinol 2007; 193: 245-50.
166. [166] Saegusa Y, Takeda H, Muto S, et al. Decreased plasma ghrelin contributes to anorexia following novelty stress. Am J Physiol Endocrinol Metab 2011; 301: E685-96.
167. [167] Rüter J, Kobelt P, Tebbe JJ, et al. Intraperitoneal injection of ghrelin induces Fos expression in the paraventricular nucleus of the hypothalamus in rats. Brain Res 2003; 991: 26-33.
168. [168] Charney DS, Deutch A. A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Crit Rev Neurobiol 1996; 10: 419-46.
169. [169] Yushun L, Fenling F, Hongyan T, et al. Role of ghrelin in cognitive impairment of hypertensive elders with chronic psychological distress. Journal of Medical Colleges of PLA 2012; 25: 163-72.
170. [170] Emül HM, Serteser M, Kurt E, Ozbulut O, Guler O, Gecici O. Ghrelin and leptin levels in patients with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1270-4.